Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.

Peripheral T-cell lymphomas (PTCL), a subdivision of T-cell non-Hodgkin lymphomas (NHLs) and distinct from the more common cutaneous T-cell lymphomas, are a diverse group of disorders that, for the most part, carry a poor prognosis. Classification of PTCL is complex, has resulted in many classification schemes, and has been further hampered by a paucity of molecular markers. Older lymphoma classification systems include the Rappaport system, which was used until the mid 1970s,1  the Kiel system, introduced in 1974,2  and the National Cancer Institute's Working Formulation, introduced in the 1980s.3  The work of Lukes, Collins, and Lennert in the 1970s first suggested that the T-cell lymphomas should be identified as distinct from B-cell lymphoma, but this was initially met with skepticism. In 1994, the International Lymphoma Study Group proposed the REAL classification (revised European-American Classification of Lymphoid Neoplasms), which featured the major histologic, immunologic, and genetic characteristics of B- and T-cell neoplasms and Hodgkin lymphoma.4  A clinical evaluation of the International Lymphoma Study Group classification of NHL published in 1997 concluded that the classification could be readily applied and identified clinically distinctive types of NHL.5 

The International Lymphoma Epidemiology Consortium (InterLymph) proposed in 2007 a nested classification of lymphoid neoplasm subtypes.6  They based their classification on the World Health Organization (WHO) classification of lymphoid neoplasms7  and the International Classification of Diseases for Oncology (3rd ed).8  The fourth edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues was published in 2008.9  The new WHO classification includes many additional subtypes of PTCL (Table 1); nevertheless, it does not necessarily help clinicians determine the best therapeutic strategy for each specific subtype. The International PTCL Project is a collaborative effort that was designed to gain better understanding of the distribution and outcomes of aggressive T-cell lymphomas. A total of 22 institutions and more than 1300 eligible patients in North America, Europe, and Asia participated in and submitted clinical and pathologic information on PTCLs diagnosed and treated at their respective centers.10 

Table 1

Old and new WHO classifications of PTCLs

Old WHO classification7 New WHO classification9 
Precursor T-cell lymphoma  
T-lymphoblastic lymphoma/leukemia  
Mature T-cell lymphomas  
T-cell prolymphocytic leukemia T-cell prolymphocytic leukemia 
T-cell granular lymphocytic leukemia T-cell large granular lymphocytic leukemia 
Aggressive NK-cell leukemia Aggressive NK-cell leukemia 
 Indolent large granular NK-cell lymphoproliferative disorder (provisional) 
ATL/adult T-cell leukemia (HTLV1+ATL/adult T-cell leukemia 
Extranodal NK-/T-cell lymphoma, nasal type Extranodal NK-/T-cell lymphoma, nasal type 
Enteropathy-type T-cell lymphoma EATL 
Hepatosplenanic T-cell lymphoma Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma (αβ only) 
 Primary cutaneous γδ T-cell lymphoma 
Mycosis fungoides/Sézary syndrome Mycosis fungoides/Sézary syndrome 
Anaplastic large-cell lymphoma, systemic or cutaneous ALCL: ALK+ 
 ALCL: ALK (provisional) 
PTCL, unspecified PTCL, NOS 
AITL AITL 
 Primary cutaneous CD30+ T-cell LPD 
     LYP and primary cutaneous ALCL 
 Primary cutaneous CD4+ small/medium T-cell lymphoma (provisional) 
 Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional) 
 Systemic EBV+ T-cell LPD of childhood 
 Hydroa vacciniforme-like lymphoma 
Old WHO classification7 New WHO classification9 
Precursor T-cell lymphoma  
T-lymphoblastic lymphoma/leukemia  
Mature T-cell lymphomas  
T-cell prolymphocytic leukemia T-cell prolymphocytic leukemia 
T-cell granular lymphocytic leukemia T-cell large granular lymphocytic leukemia 
Aggressive NK-cell leukemia Aggressive NK-cell leukemia 
 Indolent large granular NK-cell lymphoproliferative disorder (provisional) 
ATL/adult T-cell leukemia (HTLV1+ATL/adult T-cell leukemia 
Extranodal NK-/T-cell lymphoma, nasal type Extranodal NK-/T-cell lymphoma, nasal type 
Enteropathy-type T-cell lymphoma EATL 
Hepatosplenanic T-cell lymphoma Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma (αβ only) 
 Primary cutaneous γδ T-cell lymphoma 
Mycosis fungoides/Sézary syndrome Mycosis fungoides/Sézary syndrome 
Anaplastic large-cell lymphoma, systemic or cutaneous ALCL: ALK+ 
 ALCL: ALK (provisional) 
PTCL, unspecified PTCL, NOS 
AITL AITL 
 Primary cutaneous CD30+ T-cell LPD 
     LYP and primary cutaneous ALCL 
 Primary cutaneous CD4+ small/medium T-cell lymphoma (provisional) 
 Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional) 
 Systemic EBV+ T-cell LPD of childhood 
 Hydroa vacciniforme-like lymphoma 

The WHO classification for PTCLs was updated in 2008. The new classification expanded some existing disease types and added several new provisional diseases.

WHO indicates World Health Organization; PTCL, peripheral T-cell lymphoma; NK, natural killer; HTLV1, human T-lymphotropic virus type 1; EATL, enteropathy-associated T-cell lymphoma; and ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; and NOS, not otherwise specified.

Treatment advances in PTCLs have been slow compared with other lymphomas. Very often, PTCL patients are treated with the same therapy used in B-cell lymphomas, but this approach generally has a very poor outcome. Relapse is common after the administration of most currently available agents, and there are few effective options for salvage therapy. In addition, only small numbers of patients have each type of PTCL, which further complicates studying new treatments for these diseases in clinical trials.

The WHO classification system classifies the mature T-cell lymphomas into 4 groups based on their clinical features. Most of the aggressive T-cell lymphomas are included within the nodal, extranodal, and leukemic groups.

The nodal lymphoma group includes PTCL, not otherwise specified (NOS), accounting for 25.9% of cases,10  anaplastic large cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL). ALCL is further separated into the ALK+ and ALK entities. The ALK ALCLs are morphologically and immunophenotypically similar to ALK+ ALCL but lack ALK expression and have distinctive molecular features.11  According to the International PTCL study, ALK+ ALCL accounts for 6.6% and ALK ALCL for 5.5% of PTCL cases.10  The cutaneous ALCLs are included as a separate disease entity because their treatment and prognosis are distinct from the systemic ALCLs. AITL is the second largest category, accounting for 18.5% of cases in the International PTCL Project.10  The lymphoepithelioid cell variant appears to be distinct from the others and is usually characterized by CD8+ T cells and a predominance of epithelioid cells in the background.12 

The extranodal group includes a number of less common entities described primarily by their tissue tropism. Hepatosplenic γδ T-cell lymphoma is a disease of children and young adults,13,14  accounting for 1.4% of PTCL cases.10  This tumor is derived from immature or nonactivated γδ T cells, which infiltrate the liver, spleen, and bone marrow sinusoids. A characteristic chromosomal abnormality is isochromosome 7q, and patients with hepatosplenic T-cell lymphoma often have a poor outcome with a median survival of less than 2 years. The disease is more common in young males who often present with B-symptoms and cytopenias. The cells are typically CD2+, CD3+, CD4, CD5, CD7+, CD8+, or CD8 and may express natural killer (NK) markers as well.

Enteropathy-associated T-cell lymphoma (EATL) accounts for 4.7% of cases of T-cell lymphoma.10  EATL is more common in geographic areas with a higher incidence of celiac disease, as evidenced by the fact that it represents 5.8% and 9.1% of the PTCLs in North America and Europe, respectively, but only 1.9% of those in Asia. The disease often presents with pain, weight loss, and bowel perforation. There are 2 morphologic variants that are the pleomorphic type, associated with celiac disease and usually CD3+, CD7+, and CD56, and the monomorphic type, which is CD56+ and often not associated with celiac disease.15  Chromosomal abnormalities found in EATL include gains at chromosome 9q33-q34 in up to 70% of cases.16  The intestinal T- and NK-cell lymphomas diagnosed in Asian countries are associated with Epstein-Barr virus (EBV) infection and are part of the spectrum of nasal-type NK-/T-cell lymphoma.17  The mucocutaneous γδ T-cell lymphomas,18  the nasal type NK-/T-cell lymphomas, and even ALCLs can present as an intestinal lymphoma.19,20 

Panniculitis-like T-cell lymphomas constitute only 0.9% of PTCLs, and in the International PTCL Project were more common in men (75% of cases) than in women. Patients usually present with subcutaneous nodules that may become necrotic. The neoplastic cells are typically CD3+, CD4, and CD8+, with either T-cell receptor (TCR)–α/β+ or TCR-γ/δ+ and infiltrate in a rim-like fashion around the fat cells. The γδ panniculitis-like T-cell lymphomas have now been reclassified as cutaneous γδ T-cell lymphoma because their outcome is significantly inferior to that of patients with the αβ type.21 

The leukemia group consists of adult T-cell lymphoma (ATL) associated with human T-lymphotropic virus type I (HTLV-1), T-cell chronic large granular lymphocytic (LGL) leukemia, aggressive NK-cell leukemia, and T-cell prolymphocytic leukemia. Most patients with LGL leukemia have an indolent disorder that is often associated with neutropenia and can be treated with immunosuppressive agents, whereas those with aggressive NK-cell leukemia and ATL often have a poor outcome.

Several other types are delineated in the WHO classification: hydroa vacciniforme-like lymphoma, which is usually of a T-cell origin, NK-cell lymphoma caused by mosquito bite allergy, and systemic EBV-positive T-cell lymphoproliferative disease of childhood, which is part of the spectrum of chronic, active EBV infection.

Based on the United States Surveillance, Epidemiology, and End Results registry, the incidence of PTCL is < 1 case per 100 000 people in the United States.22  Results from the International PTCL Project showed that, around the world, the most common subtypes are the nodal T-cell lymphomas, with PTCL-NOS (25.9%) being the most frequent, along with AITLs (18.5%) and the ALCLs (12%). NK-/T-cell lymphomas composed 10.4%, whereas enteropathy-associated T-cell lymphomas (4.7%), hepatosplenic T-cell lymphomas (1.4%), and panniculitis-like T-cell lymphomas (0.9%) were rare, even in this large study. Among the common subtypes, there are regional differences in frequency. PTCL-NOS is more common in North America and less common in the European and Asian countries; AITL is more common in Europe than in Asia or North America; ALK+ ALCL is more common in North America; ALK ALCL is slightly more common in Europe; and the NK-/T-cell lymphomas and ATL are more common in Asia.23  The epidemiology of EATL is closely associated with the human leukocyte antigen DQ, which results in either overt or silent celiac disease, a European disease.24  The EBV-associated lymphoproliferative, T-cell, and NK-cell neoplasms are seen mainly in Japan, Korea, and Northern China, but also in Native American populations from Central and South America. NK-cell nasal and nasal-type lymphomas, occurring more frequently in Asia and Latin America, have a greater incidence in males than in females.

The increased incidence of T-NK-cell lymphomas in East Asia related to the frequency of endemic HTLV-1 and EBV infections. The HTLV-1 virus was first identified by Gallo's group at the National Cancer Institute from a cell line established from a patient with cutaneous T-cell lymphoma.25  At the same time, Yoshida et al in Japan identified a retrovirus that was immunoreactive to sera from patients with T-cell leukemia.26  The unique genome structure of HTLV-1 identified it as distinct from any other animal retroviruses, thus founding a new retroviral group. Other members of this viral group include HTLV-2, STLV, and BLV. Viral transmission is thought to require the transfer of live infected T lymphocytes, that is, T cells in breast milk, T cells in semen, and fresh T cells in blood carriers of HTLV-1 proviruses.

HTLV-1-associated lymphoma

HTLV-1-associated lymphomas include ATL, smoldering ATL, which is characterized by small numbers of circulating leukemia cells without nodal involvement, lymphomatous ATL, which presents with lymphadenopathy without leukemic involvement, and chronic ATL, which is characterized by skin lesions, leukemic, nodal, and visceral disease without hypercalcemia, gastrointestinal involvement, bone, or central nervous system disease. The geographic distribution is reflective of the areas where HTLV-1 infections are prevalent, specifically Japan and the Caribbean basin. ATL is characterized by a clonal expansion of CD4+ T lymphocytes frequently associated with skin rash, lymph node and visceral involvement, and hypercalcemia. It is suggested that the transformation of T cells in the early stages of ATL is mediated by HTLV-1 Tax protein and persistent nuclear factor-κB activation.

Angioimmunoblastic T-cell lymphoma

AITL shows distinctive features, with a polymorphous infiltrate containing medium-sized neoplastic cells, prominent arborizing blood vessels, proliferation of follicular dendritic cells, and scattered EBV+ B-cell blasts.27  Recent studies indicate that AITL is derived from the unique T-cell subset located in the germinal center, which are called the follicular helper T cells (TFH).28-31  Viruses have been implicated in the transformation of these TFH cells. Besides EBV, which is found in B-cell blasts and is likely to play a role in the development of an EBV-associated B-cell lymphoma in some AITL patients, HHV6B, another human herpes virus, has been reported in approximately half of AITL cases. Although viral infection most probably reflects the underlying immune dysfunction, it could also suggest that EBV and/or HHV6B may modulate cytokines, chemokines, and membrane receptors.

NK-/T-cell lymphoma

NK-cell lymphomas include extranodal NK-/T-cell lymphoma, nasal type, blastic NK-cell lymphoma, and aggressive NK-cell leukemia account for 10.4% of PTCL cases. Most NK-cell lymphomas have been recognized and are included in the classification of lymphoid neoplasms, but some other NK-cell lineage neoplasms are not yet categorized by the WHO. These include myeloid/NK-cell precursor acute leukemia, precursor NK-cell acute lymphoblastic leukemia, and chronic reactive NK-cell lymphocytosis.32  EBV has been implicated and found in the tumor cells of nasal/NK-cell lymphomas and aggressive NK-cell leukemia.33  However, there may be other causative factors. In one recent study from China, the occurrence of epithelial carcinomas in 10 of 23 cases of NK-/T-cell lymphoma of the oral cavity suggests that other oncogenic factors may be implicated as well as EBV.34 

Overall, patients with PTCL had a very poor outcome compared with patients with aggressive B-cell lymphomas.10  The International T-cell Lymphoma Study demonstrated that the overall survival (OS) and failure-free survival (FFS) with PTCL-NOS at 10 to 15 years was 10% (Figure 1). The International Prognostic Index (IPI), when applied to patients with aggressive T-cell lymphomas, identified a group with high IPI score who had an adverse outcome compared with patients with low IPI, similar to diffuse large B-cell lymphoma.35  However, even patients in the best prognostic category did not have a favorable outcome, and patients in the highest risk category had very short survival. When examined by histopathologic subset, the 5-year OS for patients with PTCL-NOS and AITL with IPI of 0 to 1 were 56% and 50%, respectively, whereas those with IPI of 4 or 5 were 11% and 25%, respectively. For patients with ALCL, the 5-year survivals for IPI 0 to 1 patients were excellent at 90% and 74% for ALK+ and ALK patients, respectively; however, patients with IPI of 4 to 5 had a poor outcome with 5-year survivals of 33% and 13%, suggesting that IPI is an important predictor, even in ALK+ patients.23  The IPI has not been predictive of outcome in patients with ATLL, enteropathy-associated and hepatosplenic T-cell lymphoma, or extranasal NK-/T-cell lymphoma.

Figure 1

OS of patients with the common subtypes of PTCL. Data from Vose et al10 with permission.

Figure 1

OS of patients with the common subtypes of PTCL. Data from Vose et al10 with permission.

Close modal

A new prognostic index specifically designed for PTCL,36  the prognostic index for PTCL (PIT), is similar to the IPI, including age, lactate dehydrogenase, performance status, and then bone marrow involvement. When applied to patients with PTCL-NOS, the index separated patients into more specific prognostic groups than the IPI. Of 322 patients studied, 20% had no adverse features, 34% had one feature, 26% had 2 features, and 20% had 3 or more. The 5-year OS for the most favorable group with no adverse prognostic features was 62% compared with 18% for patients with 3 or 4 adverse prognostic factors.

Aside from conventional histopathology, chemokine expression and proliferative signature have been shown to have prognostic significance, including p53 and Ki-67 (Table 2). In one study, p53 was the most important prognostic factor and was correlated with expression of P-glycoprotein, which confers resistance to chemotherapy.37  In addition, 40% to 60% of patients with PTCL express BCL2- and BCLXL-associated proteins.38  ALK+ ALCL is usually BCL2 negative, whereas other subtypes with worse outcomes may be BCL2+.

Table 2

Biologic factors and outcome in PTCL

VariablePrognostic significance
p53 Worse 
Ki-67 Worse 
BCL-2, BCL-XL Worse 
CD26 Worse 
EBV Worse 
MDR Worse 
CCND2 Worse 
CCR4 Worse 
NF-κB Favorable 
CCR3 Favorable 
CXCR3 variable 
PRDM1 Worse 
ALK-1 Favorable 
TCR BF1 Favorable 
TCR gamma1 Worse 
VariablePrognostic significance
p53 Worse 
Ki-67 Worse 
BCL-2, BCL-XL Worse 
CD26 Worse 
EBV Worse 
MDR Worse 
CCND2 Worse 
CCR4 Worse 
NF-κB Favorable 
CCR3 Favorable 
CXCR3 variable 
PRDM1 Worse 
ALK-1 Favorable 
TCR BF1 Favorable 
TCR gamma1 Worse 

TCR indicates T-cell receptor.

Two chemokine receptors, CXCR3 and CCR4, were found to be expressed in 63% and 34% of PTCL-NOS cancers, respectively.8  The dominant chemokine expression found in this study was CXCR3-positive/CCR4-negative; this phenotype was shown by multivariate analysis to be an independent prognostic factor and significantly prognostic of a poor prognosis in both PTCL-NOS and ALK-negative ALCL.

In a study reported by Rudiger et al of PTCL-NOS category, which excludes AITL, the presence of > 70% transformed blasts, > 25% Ki67 proliferation, CD56 and CD30 expression, EBV infection, and a background of > 10% CD8+ cells were all adverse prognostic factors.39  The results indicated that immunophenotyping is absolutely necessary to determine prognosis. In another study, multivariate analysis of all prognostic factors indicated that, on controlling for IPI, if the number of transformed cells is > 70%, the hazard ratio for OS is 2.2 and 1.6 for FFS.40  In patients with ALCL, the presence of the small cell variant can be associated with a worse prognosis. Finally, the expression of cytotoxic molecules also has an adverse impact on survival.41 

Several studies of gene expression profiling of PTCLs have been published. Importantly, expression profiling of purified normal T-cell subpopulations has provided the framework for understanding cell-of-origin and functional properties of T-cell malignancies.42-47  In aggregate, these studies have helped define the normal counterpart of several specific PTCLs, identified pathways frequently altered in PTCL, including nuclear factor-κB signaling and cell cycle deregulation, and highlighted the importance of proliferation as a potential biomarker for prognosis.48-57  However, most of these studies are largely underpowered to allow definitive statements regarding survival prediction. Large sample sizes will be needed to build molecular outcome predictors in PTCL and will probably require international collaboration.

More recently, gene expression profiling studies of larger numbers of patients have been undertaken and do provide novel insights into several PTCL entities.58,59  Iqbal et al studied 144 cases and were able to confirm several previous observations.58  In addition, they were able to show a major role for the microenvironment in AITL and developed a 15-gene outcome predictor highly correlated with survival and independent of the IPI. Similarly, they discovered a subgroup of PTCL-NOS with cytotoxic characteristics and inferior survival. Huang et al studied a much smaller number of extranodal NK-/T-cell lymphomas, nasal type by combining microarray analysis with array comparative genomic hybridization.59  These authors established marked differences in gene expression in these tumors compared with normal NK cells, particularly the significant overexpression of granzyme H; provided evidence for overexpression of PDGFRA similar to PTCL-NOS; and suggested a possible role for the novel tumor suppressor gene, HACE1, mapping to the 6q21 region, in NK-/T-cell lymphomas.

Classic cytogenetic studies have also provided insight into copy number alterations in PTCL (Table 3).60  A recent study of PTCL-NOS, AITL, and ALK ALCL revealed recurrent alterations associated with specific entities, including gains of 5q, 21, and 3q in AITL, commonly associated with trisomies of chromosome 5 and 21. Loss of genetic material involving chromosome 6q was also frequent. ALK ALCL was characterized by gains of 1q and 3p and losses of 16pter, 6q13-21, 15, 16qter, and 17p13. PTCL-NOS showed frequent gains of 7q22-31, 1q, 3p, 5p, and 8q24qter and losses of 6q22-24 and 10p13pter. Cases with a complex karyotype had shorter OS.

Table 3

Cytogenetics of PTCL subtypes

TCRChromosomal/histopathologic featuresDistinguishing features5-year survival, %
PTCL-NOS αβ Loss 13q22.3 adverse prognosis; gains 8q,9p,19q,loss 3q,9p Heterogeneous, variable morphology 20-30 
AITL αβ Follicular dendritic cell signature CXCL13+, PD-1+; gains 2,5,13q22.3 adverse prognosis Immunodeficiency and immune dysregulation Helper B cells may respond to cyclosporine 32 
ALCL ALK+ αβ (2,5) translocation; gain 1q, loss6q, 13q Bone marrow involvement in only 29%, median age 34 y 70 
ALK ALK αβ Pax 5, CD15 Median age 58 y 49 
NK-/T-cell  CD56+, often EBV+ Stage I/II patients respond to radiotherapy or radiochemotherapy Serum EBV copy number predictive of outcome Nasal type 64 Extranasal type < 20 
SPTCL- αβ SPTCL- γδ Αβ γδ CD3+CD8+CD565q,13q gains CD3+CD8 CD56+/− Nodules and plaques nodules, often ulceration Hemophagocytic syndrome 82; 11 
Hepatosplenic T-cell lymphoma γδ Isochromosme 7q, CD3+, CD4CD8, may be CD56+ Infiltration of sinusoids in liver, spleen, bone marrow Erythrophagocytosis 2-year OS 20 
EATL αβ Gains at chromosome 9q33-q34 CD3+ CD7+, may be CD8+ CD56+ with monomorphic type Associated with celiac sprue, malabsorption 
TCRChromosomal/histopathologic featuresDistinguishing features5-year survival, %
PTCL-NOS αβ Loss 13q22.3 adverse prognosis; gains 8q,9p,19q,loss 3q,9p Heterogeneous, variable morphology 20-30 
AITL αβ Follicular dendritic cell signature CXCL13+, PD-1+; gains 2,5,13q22.3 adverse prognosis Immunodeficiency and immune dysregulation Helper B cells may respond to cyclosporine 32 
ALCL ALK+ αβ (2,5) translocation; gain 1q, loss6q, 13q Bone marrow involvement in only 29%, median age 34 y 70 
ALK ALK αβ Pax 5, CD15 Median age 58 y 49 
NK-/T-cell  CD56+, often EBV+ Stage I/II patients respond to radiotherapy or radiochemotherapy Serum EBV copy number predictive of outcome Nasal type 64 Extranasal type < 20 
SPTCL- αβ SPTCL- γδ Αβ γδ CD3+CD8+CD565q,13q gains CD3+CD8 CD56+/− Nodules and plaques nodules, often ulceration Hemophagocytic syndrome 82; 11 
Hepatosplenic T-cell lymphoma γδ Isochromosme 7q, CD3+, CD4CD8, may be CD56+ Infiltration of sinusoids in liver, spleen, bone marrow Erythrophagocytosis 2-year OS 20 
EATL αβ Gains at chromosome 9q33-q34 CD3+ CD7+, may be CD8+ CD56+ with monomorphic type Associated with celiac sprue, malabsorption 

PTCL indicates peripheral T-cell lymphoma; TCR, T-cell receptor; NOS, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; NK, natural killer; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; and EATL, enteropathy-associated T-cell lymphoma.

Although many subtypes of PTCL are characterized by clonal expansion of TCR rearranged lymphocytes, this may not be a characteristic of all cases of NK neoplasms. Two studies recently examined the lack of TCR rearrangements in these patients and reported rearrangements at the TCR locus in 0.8% to 1.2% of cases.61,62 

Comparative genomic hybridization was used to examine genomic alterations in patients with ALK+ and ALK ALCL. A study of 74 patients showed that ALK+ ALCL samples had gains of 17p and losses of 4q13-q21 and 11q14, whereas gains of 1q and 6p21 were more frequent in ALK samples.11  Another study, which used genomic profiling in patients with PTCL-NOS (n = 42) and ALK ALCL (n = 37),63  showed that genetics of PTCL-NOS and ALK ALCL differ substantially from other T-cell lymphomas, including EATL, T-cell prolymphocytic leukemia, and ATL. Those with PTCL-NOS had recurrent chromosomal gains, high-level amplifications, and recurrent chromosomal losses on 13q, 6q, 9p, 10q, 12q, and 5q. Cutaneous ALCL and ALK+ ALCL did not show imbalances, whereas ALK ALCL showed chromosomal gains of 1q and losses of 6q and 13q.

Lastly, it is probable that significant progress in our understanding of the genetic complexity of PTCL will require an international effort to study a number of well-annotated cases using next-generation sequencing strategies.64  It can safely be hypothesized that this approach will yield important information about recurrent mutations and novel fusions that underlie the critical events in the biology of these tumors. Matched constitutional DNA will be required to properly annotate all of the somatic changes.

Standard first-line therapy

T-cell lymphomas have traditionally been treated much like the B-cell lymphomas, with a combination chemotherapy regimen. CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was the most widely used, although there were no randomized studies that proved that it was the best therapy. A retrospective meta-analysis of 2912 patients treated with CHOP or CHOP-like regimens reported a 5-year OS of 37%.65  Several groups have tried more intensive chemotherapeutic treatments for PTCL patients. The French Groupe d'Etude des Lymphomes de l'Adulte (GELA) used more intensive chemotherapy: ACVBP (dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus consolidation with autologous stem cell transplantation (ASCT) for younger, fitter patients.66  The German High Grade Non-Hodgkin Lymphoma Study Group used several variations of CHOP,67,68  and an Italian group used high-dose sequential chemotherapy with ASCT.69  The M. D. Anderson Cancer Center used an alternating triple therapy regimen and hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone).70  The GELA demonstrated that ACVBP had higher toxicity but superior event-free survival and OS compared with CHOP.71  CHOP-14 proved superior to CHOP-21 or CHOP plus etoposide in elderly patients,68  and CHOP plus etoposide should be used in younger patients.67 

Anthracycline-containing regimens for PTCL have been associated with median 5-year OS rates < 40%.65  ALCL patients have better outcomes than non-ALCL patients, with an overall response rate (ORR) > 75% and 5-year OS rates > 60%.23  ALK+ ALCL patients have slightly higher OS and FFS rates compared with ALK ALCL patients, but this may be the result of a difference in age, as ALK+ patients tend to be younger than ALK patients. However, even in ALK+ ALCL patients, 5-year FFS rates were only 49%, suggesting a definite need for new therapies or different subtype-specific treatments. It is unclear why patients with aggressive T-cell lymphomas are less responsive to conventional B-cell lymphoma regimens, but data are emerging regarding the expression of P-glycoprotein and other drug resistance pathways in subsets of patients, particularly patients with NK-/T-cell lymphomas.

Novel approaches

New therapeutic approaches and the incorporation of novel agents into these therapeutic regimens are necessary to improve the outcome for PTCL patients. Table 4 lists some of the new agents that are currently being used or are in clinical trials.

Table 4

Novel agents in use or trials in PTCL

Type of agentNameDescriptionDisease(s)Status
Antifolates Pralatrexate 10-Deazaminopoterin PTCL, CTCL Approved for PTCL 
Conjugates LMB-2 Anti-Tac) anti-CD25 fused to Pseudomonas toxin CTCL, PTCL (especially ATLL) Phase 2 
Denileukin diftitox IL-2 targeting domain fused with diphtheria toxin CTCL, PTCL Approved for CTCL 
 Brentuximab vedotin CD30 antibody conjugated to monomethylauristan-E CD30+ T-cell lymphoma Phase 2 
HDAC inhibitors Belinostat PXD101 CTCL, PTCL Phase 2 
Panobinostat LBH589 CTCL, ATL Phase 2 
Romidepsin Depsipeptide CTCL, PTCL Approved for CTCL 
Vorinostat Suberoylanilide hydroxamic acid CTCL Approved for CTCL 
Immunomodulatory agents Lenalidomide Derivative of thalidomide PTCL, CTCL Phase 2 
Immunosuppressive agents Cyclosporine Inhibitor of the NF-AT transcription complex AITL Phase 2 
Monoclonal antibodies Alemtuzumab Anti-CD52 PTCL Phase 3 
Bevacizumab Anti-VEGF PTCL (especially AITL), NK-cell Phase 2 
Iratumumab Anti-CD30 CD30+ ALCL Phase 1/2 
KW-0761 Anti-CCR4 ATLL, PTCL Phase 2 
SGN-30 Anti-CD30 CD30+ ALCL Phase 2 
Siplizumab Anti-CD2 PTCL, NK-cell, ATLL Phase 1 
Zanolimumab Anti-CD4 CTCL, PTCL Phase 2 
Nucleoside analogs Cladribine Purine nucleoside analog PTCL Phase 4 
Clofarabine Purine nucleoside analog PTCL, NK-cell Phase 1/2 
Fludarabine Purine nucleoside analog PTCL, CTCL Phase 2 
Forodesine Metabolic enzyme inhibitor PTCL, CTCL Phase 2 
Gemcitabine Pyrimidine nucleoside analog PTCL Phase 2 
Nelarabine Purine nucleoside analog T-ALL, T-NHL Phase 2 
Pentostatin Metabolic enzyme inhibitor PTCL Phase 2 
Proteasome inhibitors Bortezomib Proteasome inhibitor CTCL Phase 2 
Signaling inhibitors Enzastaurin Selective inhibitor of protein kinase C PTCL, CTCL Phase 2 
R788 Syk inhibitor PTCL Phase 2 
Type of agentNameDescriptionDisease(s)Status
Antifolates Pralatrexate 10-Deazaminopoterin PTCL, CTCL Approved for PTCL 
Conjugates LMB-2 Anti-Tac) anti-CD25 fused to Pseudomonas toxin CTCL, PTCL (especially ATLL) Phase 2 
Denileukin diftitox IL-2 targeting domain fused with diphtheria toxin CTCL, PTCL Approved for CTCL 
 Brentuximab vedotin CD30 antibody conjugated to monomethylauristan-E CD30+ T-cell lymphoma Phase 2 
HDAC inhibitors Belinostat PXD101 CTCL, PTCL Phase 2 
Panobinostat LBH589 CTCL, ATL Phase 2 
Romidepsin Depsipeptide CTCL, PTCL Approved for CTCL 
Vorinostat Suberoylanilide hydroxamic acid CTCL Approved for CTCL 
Immunomodulatory agents Lenalidomide Derivative of thalidomide PTCL, CTCL Phase 2 
Immunosuppressive agents Cyclosporine Inhibitor of the NF-AT transcription complex AITL Phase 2 
Monoclonal antibodies Alemtuzumab Anti-CD52 PTCL Phase 3 
Bevacizumab Anti-VEGF PTCL (especially AITL), NK-cell Phase 2 
Iratumumab Anti-CD30 CD30+ ALCL Phase 1/2 
KW-0761 Anti-CCR4 ATLL, PTCL Phase 2 
SGN-30 Anti-CD30 CD30+ ALCL Phase 2 
Siplizumab Anti-CD2 PTCL, NK-cell, ATLL Phase 1 
Zanolimumab Anti-CD4 CTCL, PTCL Phase 2 
Nucleoside analogs Cladribine Purine nucleoside analog PTCL Phase 4 
Clofarabine Purine nucleoside analog PTCL, NK-cell Phase 1/2 
Fludarabine Purine nucleoside analog PTCL, CTCL Phase 2 
Forodesine Metabolic enzyme inhibitor PTCL, CTCL Phase 2 
Gemcitabine Pyrimidine nucleoside analog PTCL Phase 2 
Nelarabine Purine nucleoside analog T-ALL, T-NHL Phase 2 
Pentostatin Metabolic enzyme inhibitor PTCL Phase 2 
Proteasome inhibitors Bortezomib Proteasome inhibitor CTCL Phase 2 
Signaling inhibitors Enzastaurin Selective inhibitor of protein kinase C PTCL, CTCL Phase 2 
R788 Syk inhibitor PTCL Phase 2 

There are several other experimental agents in various stage clinical trials for T-cell lymphoma.

PTCL indicates peripheral T-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ATLL, adult T-cell lymphoma; HDAC, histone deacetylase; NF-AT, nuclear factor of activated T cell; AITL, angioimmunoblastic T-cell lymphoma; NK, natural killer; ALCL, anaplastic large cell lymphoma; T-ALL, T-cell acute lymphoblastic leukemia; and T-NHL, T-cell non-Hodgkin lymphoma.

Monoclonal antibodies and immunoconjugates

The addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens, such as CHOP, has significantly improved treatment outcomes in B-cell lymphoma. As such, several monoclonal antibodies and targeted immunoconjugates and fusion proteins are currently being tested in PTCL, including alemtuzumab, iratumumab, siplizumab, zanolimumab, denileukin diftitox, and brentuximab vedotin.

Alemtuzumab, an anti-CD52 monoclonal antibody, has been shown to have activity in heavily treated patients with PTCL with an ORR of 36% in one early study.72  Alemtuzumab has been used in combination with CHOP or EPOCH (etoposide, prednisone, vincristine, cyclophophamide, and doxorubicin) with some success in PTCL, with half of patients achieving a complete response (CR).73,74  Another study compared combinations of alemtuzumab with CHOP, EPOCH, and IMVP16-PL (ifosfamide plus mesna, methotrexate, etoposide, and prednisone),75  and a third study used alemtuzmab with CHOP and ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in newly diagnosed PTCL patients.76  Although overall response rates have been high, there has been an increased risk of opportunistic infections associated with the immunosuppressive effects of alemtuzumab. Patients on these trials have required routine surveillance for reactivation of cytomegalovirus. A randomized trial comparing CHOP-14 to alemtuzumab-CHOP 14 is currently underway as a European intergroup study.

Two anti-CD30 monoclonal antibodies, iratumumab and SGN-30, have shown efficacy in CD30+ ALCL.77,78  In vitro studies have shown that both drugs are synergistic or additive with conventional chemotherapy.79-81  An immunoconjugate of SGN-30 and monomethyl auristatin, brentuximab vetodin (SGN-35), has demonstrated an ORR of 41% with a median response duration of 7.3 months in patients with relapsed and refractory CD30+ lymphomas.82  A study is currently underway to evaluate the combination of CHOP with brentiximab vetodin in newly diagnosed patients with ALCL.

Siplizumab is an anti-CD2 monoclonal antibody. CD2 is an adhesion molecule highly expressed on activated T cells and NK cells and on the majority of cells from patients with T-cell lymphoma and leukemia. Siplizumab eliminated both CD4+ and CD8+ T cells and NK cells without affecting B cells. In a phase 1 trial in patients with CD2+ lymphoproliferative disease, siplizumab showed clinical activity, inducing CRs in 2 patients with LGL leukemia, 3 partial responses (PRs) in patients with ATL, and 1 PR in a patient with cutaneous T-cell lymphoma (CTCL).83  A subsequent dose escalation study produced a PR in a patient with NK-cell LGL and a CR in a PTCL patient.84  However, siplizumab also predisposes patients to the development of lymphoproliferative syndrome,85  although it may be possible to prevent that with prophylactic rituximab.

CD4 is expressed in half of all T cells and by most CTCL and nodal PTCL cells. Zanolimumab, an anti-CD4 monoclonal antibody, is being used in both disease types, although clinical development for CTCL is farther along. Zanolimumab was shown to be active and well tolerated in a study of 21 PTCL patients, with an ORR in 24% of patients.86  Clinical studies of zanolimumab in combination with CHOP are ongoing and include a phase 1/2 dose escalation trial in patients with noncutaneous CD4+ PTCL.

Bevacizumab, an antivascular endothelial growth factor (VEGF) monoclonal antibody, will most probably have the largest impact in AITL, as AITL is characterized by the overexpression of angiogenic factors, such as VEGF. At least one relapsed AITL patient has achieved a CR after treatment with bevacizumab87  and was being studied along with CHOP in a clinical trial for patients with PTCL or NK-cell neoplasms by the Eastern Cooperative Oncology Group. However, preliminary results of this trial reported a high incidence of cardiac events related to the therapy.88 

Denileukin diftitox, a fusion protein that combines IL-2 receptor-binding domain with diphtheria toxin, has demonstrated activity in both cutaneous and aggressive T-cell lymphomas. In a single-center phase 2 study at M. D. Anderson Cancer Center, denileukin diftitox at a dose of 18 μg/kg per day for 5 days on a 21-day cycle demonstrated a response rate of 48% in heavily pretreated patients with relapsed PTCL.89  Responses were seen in 4 of 10 patients with PTCL-NOS, 2 of 3 with AITL, and 2 of 2 with ALCL. In this trial, the expression of CD25 by immunohistochemistry was not predictive of response to denileukin diftitox.

Based on these data, a combination of denileukin diftitox and CHOP was studied in untreated patients with PTCL. This study enrolled 49 patients. Denileukin diftitox was administered at 18 μg/kg per day on days 1 and 2 of each cycle, followed by CHOP chemotherapy on day 3, and granulocyte colony-stimulating factor support starting day 4 of each 21-day cycle.90  In 37 efficacy-evaluable patients (> 2 cycles), the ORR was 86% (CR 75%). Median progression-free survival (PFS) was 15 months, and 2-year estimated OS was 60%. A large randomized study comparing CHOP to denileukin diftitox with CHOP is being initiated.90 

LMB-2 is an anti-Tac (anti-CD25) single-chain monoclonal antibody conjugated to Pseudomonas toxin. LMB-2 has shown clinical activity in phase 2 trials in CLL, CTCL, and hairy cell leukemia. ATL is the PTCL subtype that is most sensitive to LMB-2, but clinical responses have been limited to do rapid disease progression after > 95% tumor reduction and immunogenic reactions.91  A phase 2 clinical trial for this population is being planned in which LMB-2 will be given after chemotherapy with fludarabine and cyclophosphamide.

HDAC inhibitors

Histone deacetylase (HDAC) inhibitors are potent inducers of histone acetylation, which results in the expression of tumor suppressor genes that had been previously silenced by deacetylation. This gene expression leads to cell cycle arrest and apoptosis. There are a number of HDAC inhibitors being used or studied in T-cell lymphoma, including vorinostat, romidepsin (also known as depsipeptide), panobinostat, and belinostat. Vorinostat and romidepsin have shown single-agent activity in CTCL,92,93  and vorinostat was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of advanced and refractory CTCL. Romidepsin was also recently FDA-approved in 2009 for advanced and refractory CTCL based on a demonstrated ORR in 2 clinical trials of 34%.94  The median response duration was 15 months (range 1-20+), and median time to progression was 8.3 months in early and 6.4 months in more advanced disease. A phase 2 study of romidepsin was completed in patients with relapsed and refractory PTCL.95  This phase 2, open-label, multiarm, multicenter study enrolled 43 PTCL patients from the National Cancer Institute and 9 extramural sites. Of 43 patients, 31 received ≥ 2 cycles of therapy. Mean number of prior therapies was 3.9 (range, 1-12). Objective response rate was 39% overall or 55% for patients who received at least 2 cycles of therapy. The overall median duration of response was 8.3 months (range, 1.6 months to 4.8+ years) for all patients. A multicenter, multinational phase 2B registration study of romidepsin at the same dose and schedule in relapsed and refractory PTCL has completed accrual and results have been recently reported. Of 130 patients with a median of 2 prior therapies, the ORR was 26% with 15% CR by radiographic documentation. The median response duration was 12 months, and toxicities included gastrointestinal and constitutional events and thrombocytopenia.

Belinostat, a hydroxamic acid-derived HDAC inhibitor, has been studied in both intravenous and oral formulations. Belinostat was administered intravenously at 1000 mg/m2 daily for 5 days every 3 weeks in 53 patients, including 19 with refractory PTCL and 29 with refractory CTCL.96  The objective response rate in PTCL was 32% with 2 CR and a median response duration of 8.9+ months, and 14% in CTCL, with a response duration of 9.1 months. A multicenter phase 2 registration trial of belinostat in relapsed PTCL patients is underway, and a cohort dose escalation study of oral belinostat is ongoing in patients with relapsed lymphoma.

Additive and synergistic activity has been demonstrated in vitro for combinations of HDAC inhibitor with a number of agents, including topoisomerase inhibitors, bortezomib, and cytotoxic chemotherapy drugs, and clinical trials are underway to explore the activity of these combinations in T-cell lymphomas.

Antifolates

Pralatrexate is a novel folate antagonist whose activity is associated with binding to the reduced folate carrier.97  In a phase 1/2 dose escalation trial of pralatrexate in refractory lymphoma patients, the ORR was 31%, with response durations ranging from 3 to 26 months.98  The response rate in that trial was 54% for patients with T-cell lymphomas. Based on these encouraging data, the PROPEL trial was initiated. In this trial, 111 patients with relapsed or refractory PTCL were treated with pralatrexate weekly for 6 weeks on a 7-week cycle. The median prior therapies was 3, and 63% of patients had no response to their last line of therapy. The ORR was 29% and the median response duration was 10.1 months. Five patients with relapsed/refractory PTCL who responded to single-agent pralatrexate went onto stem cell transplantation.99  Toxicities included mucositis in70% of patients and thrombocytopenia in 40%. Pralatrexate was approved in September 2009 by the United States FDA as a single agent to treat relapsed or refractory patients with PTCL. A number of recent studies have explored the potential synergy between pralatrexate and other active agents in T-cell lymphoma. A phase 1 study combining pralatrexate with gemcitabine is underway.

Immunomodulators and immunosuppressants

Cyclosporine is an immunosuppressive agent that inhibits the nuclear factor of activated T-cell transcription complex, which activates the genes encoding cytokines and cell surface molecules involved in cell-to-cell communication and death.100  Because AITL is characterized by immune dysregulation, cyclosporine was administered to 12 patients in a phase 2 trial.101  Two-thirds (3 CRs, 5 PRs) of the patients responded, but there were 4 deaths. A phase 2 trial of cyclosporine in AITL was conducted by Eastern Cooperative Oncology Group but closed early because of slow accrual.

Other immune-modulating and antiangiogenic agents, including bevacizumab,87  rituximab,102  lenalidomide, and thalidomide, are also being explored as single agents and in combination with chemotherapy. A phase 2 study of lenalidomide at a dose of 25 mg/m2 daily for 21 days of a 28-day cycle was conducted in 24 relapsed PTCL patients.103  The overall response rate was 30% with a PFS of 95 days. Toxicities included neutropenia and thrombocytopenia in 20% and 33% of patients, respectively.

Nucleoside analogs

Nucleoside analogs are chemotherapeutic agents that primarily inhibit DNA replication and repair. Gemcitabine is the most effective pyrimidine nucleoside analog in PTCL. It has been active both as a single agent104,105  and in combination with alemtuzumab106  and bortezomib.107,108  The purine nucleoside analogs include cladribine, fludarabine, clofarabine, and nelarabine. Both cladribine and fludarabine have shown efficacy in PTCL, and clofarabine and nelarabine are currently in several clinical trials in T-cell lymphoma.

The metabolic enzyme inhibitors, which include deoxycoformycin (pentostatin) and forodesine, do not incorporate into DNA, unlike the other nucleoside analogs. Pentostatin inhibits adenosine deaminase, increasing the deoxyadenosine triphosphate pool, and forodesine inhibits phosphorylase, increasing the deoxyguanosine triphosphate pool. Both agents have shown some efficacy in CTCL. A phase 1/2 study of oral forodesine in relapsed and refractory CTCL patients reported a 53% overall response rate, and a phase 2 trial has been completed.109 

Proteasome inhibitors

Bortezomib, a proteasome inhibitor, has been well tolerated and active as a single agent in relapsed or refractory CTCL patients.110  In a phase 2 study of bortezomib in relapsed CTCL or PTCL patients, the ORR was 67% with 2 CR and no grade 4 toxicity.110  The GELA has conducted a phase 2 study of bortezomib with ACVBP chemotherapy in 57 untreated PTCL patients and has reported that 29 patients were withdrawn prematurely because of toxicity.111  The ORRs were similar to ACVBP alone. Bortezomib has been used in combination with gemcitabine plus doxorubicin,107,108  and recent evidence shows that bortezomib may synergize with pralatrexate in T-cell lymphoma (see antifolates section above).112 

Signaling inhibitors

Enzastaurin is a selective inhibitor of protein kinase C, which acts in part through the AKT pathway. By targeting the PI3K/AKT pathways, enzastaurin inhibits cell proliferation, induces tumor cell apoptosis, and suppresses tumor-induced angiogenesis in CTCL cell lines.113  Enzastaurin is currently in 2 phase 2 trials: one for patients with several types of NHL, including PTCL and CTCL, and another for relapsed CTCL patients.

Optimal treatment approaches for patients with NK-/T-cell lymphoma have not yet been established. A phase 1/2 study of concurrent chemoradiotherapy for untreated localized NK-/T-cell lymphoma was conducted in Japan.114  Extranodal NK-/T-cell lymphoma, nasal type, is generally refractory to CHOP associated with a high expression of the multidrug resistance gene, P-glycoprotein. Patients in this trial were concurrently treated with radiotherapy and chemotherapy consisting of carboplatin, etoposide, ifosfamide, and dexamethasone. With a median follow-up of 32 months, the 2-year OS was 78% (95% confidence interval [CI], 57%-89%). This compared favorably with the historical control of radiotherapy alone (45%). Of the 26 patients assessable for a response, 20 (77%) achieved a CR, with one PR. The ORR was 81%. The most common grade 3 nonhematologic toxicity was mucositis related to radiation (30%). The investigators concluded that concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK-/T-cell lymphoma.

A novel approach for patients with advanced NK-/T-cell lymphomas incorporates L-asparaginase along with ifosfamide, etoposide, dexamethasone, and methotrexate (SMILE). Overexpression of P-glycoprotein in NK-/T-cell lymphomas has contributed to relative chemoresistance and poor outcomes after CHOP-based therapies with 5-year survivals of 20% or less in patients with advanced stage disease. Yong et al treated 18 patients who were refractory to CHOP with L-asparaginase, vincristine, dexamethasone, and involved field radiotherapy and reported a response rate and 5-year OS of 55%.115  A phase 1 study escalating methotrexate and etoposide was completed and reported a response rate of 67%. A prospective phase 2 trial has been reported with the SMILE regimen in patients with newly diagnosed stage IV or relapsed refractory NK-/T-cell lymphomas.116  Of 39 enrolled patients, 29 (74%) completed the planned treatment. The responses were complete remission (CR) in 15, partial remission in 14, and early death because of infection in 4. ORR and CR were 74% (95% CI, 58%-87%) and 38%, respectively. The most common grade 3 nonhematologic toxicity was infection (41%).

For patients with ATL, results with conventional chemotherapy regimens have been uniformly poor. A phase 3 Japanese study evaluated a combination regimen of VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone), AMP (doxorubicin, ranimustine, and prednisone), and VECP (vindesine, etoposide, carboplatin, and prednisone) against CHOP-14 in ATL.117  The study demonstrated superiority for VCAP-AMP-VECP for newly diagnosed aggressive ATL patients. A phase 2 study is in preparation to investigate the ability of allogeneic stem cell transplantation after induction with the VCAP-AMP-VECP regimen to prolong the median survival time, which is currently 13 months with the VCAP-AMP-VECP regimen.

The use of interferon and zidovudine has been shown to induce responses in up to 50% of patients with acute or lymphomatous ATL.118  In a recent meta-analysis, 116 patients with acute ATL, 18 patients with chronic ATL, 11 patients with smoldering ATL, and 100 patients with ATL lymphoma were evaluated.119  Five-year OS rates were 46% for 75 patients who received first-line antiviral therapy (P = .004), 20% for 77 patients who received first-line chemotherapy, and 12% for 55 patients who received first-line chemotherapy followed by antiviral therapy. The authors claimed that patients with acute, chronic, and smoldering ATL significantly benefited from first-line antiviral therapy, whereas patients with ATL lymphoma experienced a better outcome with chemotherapy. In acute ATL, 82% of patients were alive at 5 years with antiviral therapy, and 100% of patients with chronic and smoldering ATL were alive at 5 years. Multivariate analysis showed that first-line antiviral therapy significantly improved OS (hazard ratio = 0.47; 95% CI, 0.27-0.83; P = .021). However, considering the potential selection bias in this retrospective study, future prospective studies are needed.

Finally, a humanized anti-CCR4 antibody, KW-0761, has shown promise as a single agent in Japan for the treatment of ATL. KW-0761 was used for relapsed patients with CCR4-positive ATL and PTCL in a phase 1 study.120  The ORR was 31% (5 of 16; 95% CI, 11%-59%). There were no dose-limiting toxicities, and no anti–KW-0761 antibodies were detected.120  A phase 2 trial for relapsed ATL patients was recently completed. Of 27 enrolled patients (14 acute, 6 lymphomatous, 7 chronic ATL), the ORR was 54% with 7 CR. Toxicities included cytopenias (lymphopenia 96%, neutropenia 33%), skin rash (52%), and mild transaminitis.

Transplantation

Several retrospective studies suggest that there are populations of patients with PTCL that will benefit from transplantation. The National Cancer Consortium Network guideline includes transplantation as an option for consolidation after first remission in patients with histologies other than ALK+ ALCL and in patients with intermediate or high IPI scores. Disease status at transplantation is a major predictor of success, particularly for autologous transplantation.121  Results are better for patients who are in chemosensitive remission, whereas only 25% to 30% of refractory patients benefit.122,123  In the studies where 5-year outcomes are reported, OS and FFS average 34% and 18%, respectively.124  The single-center experience at Stanford reported only a modest benefit after autologous transplantation (5-year OS of 36%) for patients with relapsed disease and a 5-year OS of 76% in patients transplanted in first remission.125 

A prospective study from Germany using chemotherapy and up-front autologous transplantation for PTCL has been reported. The treatment regimen consisted of 4 to 6 cycles of CHOP, followed by mobilizing therapy with either dexaBEAM (dexamethasone, carmustine, melphalan, etoposide, and cytarabine) or ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin). Patients in complete or partial remission then underwent myeloablative chemoradiotherapy and ASCT. Two-thirds (66%) of the patients had a disease response to chemotherapy and thus went on to receive ASCT. At a median follow-up time of 33 months, the estimated 3-year OS and PFS for patients in CR were 48% and 36%, respectively. Patients who did not experience a response to chemotherapy and therefore did not undergo ASCT had a very poor outcome, with a median survival of less than 2 years.126  The role of autologous transplantation in second or subsequent remission is less well defined.

There are currently no randomized studies comparing outcomes between autologous and allogeneic transplantation in the United States. The Nordic and German lymphoma groups are launching a large, prospective randomized trial to compare the different strategies as consolidation after first-line therapy. In addition, the Center for International Blood & Marrow Transplant Research is currently conducting a database review comparing allogeneic and autologous transplants in PTCL patients. In a retrospective single-institution study that compared autologous and allogeneic transplantation, outcomes for autologous transplantation were best when conducted in first remission, and allogeneic transplantation was better for patients with resistant or relapsed disease.127  Further prospective studies are needed to define which subsets of PTCL patients will optimally benefit from allogeneic or ASCT.

Because of the inferior outcomes with CHOP-based regimens, novel strategies are needed for patients with aggressive T-cell lymphomas. The National Cancer Consortium Network has established evidence-based treatment approaches for T-cell lymphoma and stratifies patients based on stage. For early-stage patients with localized disease, chemotherapy should be followed by involved field radiotherapy. It is recommended that all patients except for those with low IPI be consolidated with ASCT. ALK+ ALCL is identified as the one subtype that has an excellent outcome and should not be transplanted in first remission. Recent data suggest that ALK+ patients with high IPI could be an exception to this rule. In prospective trials where up to 40% of patients do not undergo a complete remission and therefore cannot be consolidated with transplantation, new approaches are necessary.

Selection of first-line therapy based on histopathologic features has not yet been widely used but should be considered. For nodal T-cell lymphomas (PTCL-NOS, AITL, and ALCL), the standard regimen used is a CHOP-based therapy. For extranodal subtypes, regimens may be individualized. For panniculitis-like T-cell lymphoma, distinction should be made between the αβ type and the γδ type, which is now included in the category of cutaneous γδ T-cell lymphoma. The αβ patients may be treated with single-agent therapies or combination chemotherapy and generally have an excellent outcome. The cutaneous γδ T-cell lymphomas overall do poorly and should be treated with aggressive chemotherapy followed by transplantation. Likewise, hepatosplenic and intestinal T-cell lymphomas have a poor outcome. In one study, 26 enteropathy-associated T-cell lymphoma patients were treated with CHOP and then methotrexate alternating with ifosfamide, etoposide, and epirubicin.128  Patients who achieved CR went on to transplantation (n = 33). For the transplanted enteropathy-associated patients, the PFS and OS were 52% and 60%, respectively. NK-/T-cell lymphoma patients have also had inferior outcomes with CHOP-based regimens, and consideration of alternative regimens, such as SMILE and asparaginase combinations, should be strongly considered for these patients.

The role of autologous versus allogeneic stem cell transplantation in patients with poor prognosis subtypes, such as NK-/T-cell and γδ T-cell lymphomas, has not been ascertained. In retrospective series, results with these subtypes are inferior to those of the more common PTCL-NOS and AITL subtypes after autologous transplantation. Therefore, consolidation with allogeneic stem cell transplantation should be considered in patients who have appropriate donors.

In conclusion, from this summary of the current state of classification, prognosis, and therapeutic approaches in PTCL, it is apparent that much progress has been made. Although the problem with PTCL treatment in the past was a lack of available therapies, the development of novel therapies necessitates the development of paradigms to combine these agents to improve response rates and durability of responses. Based on the success of the chronic lymphocytic leukemia and the mantle cell lymphoma consortiums, investigators from North America have formed a North American PTCL Collaborative Group, which will collaborate with the International PTCL Project to develop new treatment strategies to improve outcome in PTCL. An international registry is currently open and registering patients with newly diagnosed PTCL. In addition, an international tissue bank has been initiated to capture sufficient quantities of clinically annotated and well-characterized specimens.

Contribution: F.M.F. prepared the manuscript for publication; and all authors wrote and reviewed the manuscript.

Conflict-of-interest disclosure: F.M.F. was a consultant for Eisai and Celgene and received research funding from Merck and Bayer. J.M.V. received research funding from Allos. S.T.R. was on the Scientific Advisory Board of Celgene and Genzyme, the Speakers Bureau of Merck, and the Advisory Panel of Eisai and Allos. K.T. received research funding from Kyowa Kirin, Mundipharma, and Merck. The remaining authors declare no competing financial interests.

Correspondence: Francine M. Foss, Yale Cancer Center, 333 Cedar St, FMP 112, PO Box 208032, New Haven, CT 06520-8032; e-mail: [email protected].

1
Rappaport
 
H
Discussion on: The pathology and nomenclature of Hodgkin's disease.
Cancer Res
1966
, vol. 
26
 
1
(pg. 
1082
-
1083
)
2
Older lymphoma classification and typing schemes
Lymphoma Information Network Web site
Accessed April 12, 2011 
3
National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.
Cancer
1982
, vol. 
49
 
10
(pg. 
2112
-
2135
)
4
Harris
 
NL
Jaffe
 
ES
Stein
 
H
, et al. 
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood
1994
, vol. 
84
 
5
(pg. 
1361
-
1392
)
5
Non-Hodgkin's Lymphoma Classification Project
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.
Blood
1997
, vol. 
89
 
11
(pg. 
3909
-
3918
)
6
Morton
 
LM
Turner
 
JJ
Cerhan
 
JR
, et al. 
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).
Blood
2007
, vol. 
110
 
2
(pg. 
695
-
708
)
7
Harris
 
NL
Jaffe
 
ES
Diebold
 
J
, et al. 
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
J Clin Oncol
1999
, vol. 
17
 
12
(pg. 
3835
-
3849
)
8
Percy
 
C
Fritz
 
A
Jack
 
A
, et al. 
International Classification of Diseases for Oncology (ICD-O-3)
2000
3rd ed.
Geneva, Switzerland
World Health Organization
9
World Health Organization
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
2008
4th ed
Lyon, France
IARC Press
10
Vose
 
J
Armitage
 
J
Weisenburger
 
D
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
J Clin Oncol
2008
, vol. 
26
 
25
(pg. 
4124
-
4130
)
11
Salaverria
 
I
Bea
 
S
Lopez-Guillermo
 
A
, et al. 
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.
Br J Haematol
2008
, vol. 
140
 
5
(pg. 
516
-
526
)
12
Geissinger
 
E
Odenwald
 
T
Lee
 
SS
, et al. 
Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells.
Virchows Arch
2004
, vol. 
445
 
4
(pg. 
334
-
343
)
13
Charton-Bain
 
MC
Brousset
 
P
Bouabdallah
 
R
, et al. 
Variation in the histological pattern of nodal involvement by gamma/delta T-cell lymphoma.
Histopathology
2000
, vol. 
36
 
3
(pg. 
233
-
239
)
14
Gaulard
 
P
Belhadj
 
K
Reyes
 
F
Gammadelta T-cell lymphomas.
Semin Hematol
2003
, vol. 
40
 
3
(pg. 
233
-
243
)
15
Zettl
 
A
deLeeuw
 
R
Haralambieva
 
E
Mueller-Hermelink
 
HK
Enteropathy-type T-cell lymphoma.
Am J Clin Pathol
2007
, vol. 
127
 
5
(pg. 
701
-
706
)
16
Zettl
 
A
Ott
 
G
Makulik
 
A
, et al. 
Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma.
Am J Pathol
2002
, vol. 
161
 
5
(pg. 
1635
-
1645
)
17
Au
 
WY
Weisenburger
 
DD
Intragumtornchai
 
T
, et al. 
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
Blood
2009
, vol. 
113
 
17
(pg. 
3931
-
3937
)
18
Shapira
 
MY
Caspi
 
O
Amir
 
G
Zlotogorski
 
A
Naparstek
 
Y
Gastric-mucocutaneous gammadelta T cell lymphoma: possible association with Epstein-Barr virus?
Leuk Lymphoma
1999
, vol. 
35
 
3
(pg. 
397
-
401
)
19
Kanavaros
 
P
Boulland
 
ML
Petit
 
B
Arnulf
 
B
Gaulard
 
P
Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Leuk Lymphoma
2000
, vol. 
38
 
3
(pg. 
317
-
326
)
20
Kinney
 
MC
The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms.
Am J Clin Pathol
1999
, vol. 
111
 
1 suppl 1
(pg. 
S104
-
S118
)
21
Toro
 
JR
Liewehr
 
DJ
Pabby
 
N
, et al. 
Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma.
Blood
2003
, vol. 
101
 
9
(pg. 
3407
-
3412
)
22
Morton
 
LM
Wang
 
SS
Devesa
 
SS
, et al. 
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.
Blood
2006
, vol. 
107
 
1
(pg. 
265
-
276
)
23
Savage
 
KJ
Harris
 
NL
Vose
 
JM
, et al. 
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Blood
2008
, vol. 
111
 
12
(pg. 
5496
-
5504
)
24
Verbeek
 
WH
von Blomberg
 
BM
Scholten
 
PE
, et al. 
The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease.
Am J Gastroenterol
2008
, vol. 
103
 
12
(pg. 
3152
-
3158
)
25
Posner
 
LE
Robert-Guroff
 
M
Kalyanaraman
 
VS
, et al. 
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas.
J Exp Med
1981
, vol. 
154
 
2
(pg. 
333
-
346
)
26
Yoshida
 
M
Miyoshi
 
I
Hinuma
 
Y
Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.
Proc Natl Acad Sci U S A
1982
, vol. 
79
 
6
(pg. 
2031
-
2035
)
27
Attygalle
 
AD
Kyriakou
 
C
Dupuis
 
J
, et al. 
Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
Am J Surg Pathol
2007
, vol. 
31
 
7
(pg. 
1077
-
1088
)
28
de Leval
 
L
Gaulard
 
P
Pathobiology and molecular profiling of peripheral T-cell lymphomas.
Hematology Am Soc Hematol Educ Program
2008
, vol. 
2008
 (pg. 
272
-
279
)
29
Rodriguez-Pinilla
 
SM
Atienza
 
L
Murillo
 
C
, et al. 
Peripheral T-cell lymphoma with follicular T-cell markers.
Am J Surg Pathol
2008
, vol. 
32
 
12
(pg. 
1787
-
1799
)
30
Dupuis
 
J
Boye
 
K
Martin
 
N
, et al. 
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells.
Am J Surg Pathol
2006
, vol. 
30
 
4
(pg. 
490
-
494
)
31
Grogg
 
KL
Morice
 
WG
Macon
 
WR
Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
Br J Haematol
2007
, vol. 
137
 
5
(pg. 
416
-
422
)
32
Greer
 
JP
Kinney
 
MC
Loughran
 
TP
T cell and NK cell lymphoproliferative disorders.
Hematology Am Soc Hematol Educ Program
2001
, vol. 
2001
 (pg. 
259
-
281
)
33
Yachie
 
A
Kanegane
 
H
Kasahara
 
Y
Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases.
Semin Hematol
2003
, vol. 
40
 
2
(pg. 
124
-
132
)
34
Wang
 
B
Yao
 
K
Liu
 
G
, et al. 
Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
Cell Mol Immunol
2009
, vol. 
6
 
2
(pg. 
97
-
103
)
35
Suzumiya
 
J
Ohshima
 
K
Tamura
 
K
, et al. 
The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project.
Ann Oncol
2009
, vol. 
20
 
4
(pg. 
715
-
721
)
36
Gallamini
 
A
Stelitano
 
C
Calvi
 
R
, et al. 
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.
Blood
2004
, vol. 
103
 
7
(pg. 
2474
-
2479
)
37
Pescarmona
 
E
Pignoloni
 
P
Puopolo
 
M
, et al. 
p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
J Pathol
2001
, vol. 
195
 
3
(pg. 
361
-
366
)
38
Rassidakis
 
GZ
Jones
 
D
Lai
 
R
, et al. 
BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation.
J Pathol
2003
, vol. 
200
 
2
(pg. 
240
-
248
)
39
Rudiger
 
T
Weisenburger
 
DD
Anderson
 
JR
, et al. 
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
Ann Oncol
2002
, vol. 
13
 
1
(pg. 
140
-
149
)
40
Dupuis
 
J
Emile
 
JF
Mounier
 
N
, et al. 
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.
Blood
2006
, vol. 
108
 
13
(pg. 
4163
-
4169
)
41
Asano
 
N
Suzuki
 
R
Kagami
 
Y
, et al. 
Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified.
Am J Surg Pathol
2005
, vol. 
29
 
10
(pg. 
1284
-
1293
)
42
Chtanova
 
T
Kemp
 
RA
Sutherland
 
AP
Ronchese
 
F
Mackay
 
CR
Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells.
J Immunol
2001
, vol. 
167
 
6
(pg. 
3057
-
3063
)
43
Shaffer
 
AL
Rosenwald
 
A
Hurt
 
EM
, et al. 
Signatures of the immune response.
Immunity
2001
, vol. 
15
 
3
(pg. 
375
-
385
)
44
McHugh
 
RS
Whitters
 
MJ
Piccirillo
 
CA
, et al. 
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
Immunity
2002
, vol. 
16
 
2
(pg. 
311
-
323
)
45
Herman
 
AE
Freeman
 
GJ
Mathis
 
D
Benoist
 
C
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion.
J Exp Med
2004
, vol. 
199
 
11
(pg. 
1479
-
1489
)
46
Kim
 
CH
Lim
 
HW
Kim
 
JR
, et al. 
Unique gene expression program of human germinal center T helper cells.
Blood
2004
, vol. 
104
 
7
(pg. 
1952
-
1960
)
47
Fontenot
 
JD
Rasmussen
 
JP
Williams
 
LM
, et al. 
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
Immunity
2005
, vol. 
22
 
3
(pg. 
329
-
341
)
48
Martinez-Delgado
 
B
Melendez
 
B
Cuadros
 
M
, et al. 
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes.
Clin Cancer Res
2004
, vol. 
10
 
15
(pg. 
4971
-
4982
)
49
Martinez-Delgado
 
B
Cuadros
 
M
Honrado
 
E
, et al. 
Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.
Leukemia
2005
, vol. 
19
 
12
(pg. 
2254
-
2263
)
50
Piccaluga
 
PP
Agostinelli
 
C
Zinzani
 
PL
, et al. 
Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified.
Lancet Oncol
2005
, vol. 
6
 
6
pg. 
440
 
51
Ballester
 
B
Ramuz
 
O
Gisselbrecht
 
C
, et al. 
Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.
Oncogene
2006
, vol. 
25
 
10
(pg. 
1560
-
1570
)
52
de Leval
 
L
Rickman
 
DS
Thielen
 
C
, et al. 
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
Blood
2007
, vol. 
109
 
11
(pg. 
4952
-
4963
)
53
Lamant
 
L
de Reynies
 
A
Duplantier
 
MM
, et al. 
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
Blood
2007
, vol. 
109
 
5
(pg. 
2156
-
2164
)
54
Piccaluga
 
PP
Agostinelli
 
C
Califano
 
A
, et al. 
Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
Cancer Res
2007
, vol. 
67
 
22
(pg. 
10703
-
10710
)
55
Piccaluga
 
PP
Agostinelli
 
C
Califano
 
A
, et al. 
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
J Clin Invest
2007
, vol. 
117
 
3
(pg. 
823
-
834
)
56
Rodriguez-Antona
 
C
Leskela
 
S
Zajac
 
M
, et al. 
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Blood
2007
, vol. 
110
 
9
(pg. 
3345
-
3351
)
57
Cuadros
 
M
Dave
 
SS
Jaffe
 
ES
, et al. 
Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.
J Clin Oncol
2007
, vol. 
25
 
22
(pg. 
3321
-
3329
)
58
Iqbal
 
J
Weisenburger
 
DD
Greiner
 
TC
, et al. 
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
Blood
2010
, vol. 
115
 
5
(pg. 
1026
-
1036
)
59
Huang
 
Y
de Reyniès
 
A
de Leval
 
L
, et al. 
Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK-/T-cell lymphoma, nasal type.
Blood
2010
, vol. 
115
 
6
(pg. 
1226
-
1237
)
60
Nelson
 
M
Horsman
 
DE
Weisenburger
 
DD
, et al. 
Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
Br J Haematol
2008
, vol. 
141
 
4
(pg. 
461
-
469
)
61
Leich
 
E
Haralambieva
 
E
Zettl
 
A
, et al. 
Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas.
J Pathol
2007
, vol. 
213
 
1
(pg. 
99
-
105
)
62
Feldman
 
AL
Sun
 
DX
Law
 
ME
, et al. 
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.
Leukemia
2008
, vol. 
22
 
6
(pg. 
1139
-
1143
)
63
Zettl
 
A
Rudiger
 
T
Konrad
 
MA
, et al. 
Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
Am J Pathol
2004
, vol. 
164
 
5
(pg. 
1837
-
1848
)
64
Metzker
 
ML
Sequencing technologies: the next generation.
Nat Rev Genet
2010
, vol. 
11
 
1
(pg. 
31
-
46
)
65
Abouyabis
 
AN
Shenoy
 
PJ
Flowers
 
C
Lechowicz
 
MJ
Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 3452
66
Gisselbrecht
 
C
Lepage
 
E
Molina
 
T
, et al. 
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
J Clin Oncol
2002
, vol. 
20
 
10
(pg. 
2472
-
2479
)
67
Pfreundschuh
 
M
Trumper
 
L
Kloess
 
M
, et al. 
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Blood
2004
, vol. 
104
 
3
(pg. 
626
-
633
)
68
Pfreundschuh
 
M
Trumper
 
L
Kloess
 
M
, et al. 
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Blood
2004
, vol. 
104
 
3
(pg. 
634
-
641
)
69
Corradini
 
P
Tarella
 
C
Zallio
 
F
, et al. 
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
Leukemia
2006
, vol. 
20
 
9
(pg. 
1533
-
1538
)
70
Shapiro
 
M
Wasik
 
MA
Junkins-Hopkins
 
JM
, et al. 
Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
Am J Hematol
2003
, vol. 
74
 
1
(pg. 
46
-
51
)
71
Tilly
 
H
Lepage
 
E
Coiffier
 
B
, et al. 
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Blood
2003
, vol. 
102
 
13
(pg. 
4284
-
4289
)
72
Enblad
 
G
Hagberg
 
H
Erlanson
 
M
, et al. 
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
Blood
2004
, vol. 
103
 
8
(pg. 
2920
-
2924
)
73
Janik
 
JE
Dunleavy
 
K
Pittaluga
 
S
, et al. 
A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies [abstract].
Blood
2005
, vol. 
106
 
11
 
Abstract 3348
74
Gallamini
 
A
Zaja
 
F
Patti
 
C
, et al. 
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
Blood
2007
, vol. 
110
 
7
(pg. 
2316
-
2323
)
75
Kim
 
JS
Kim
 
S-J
Lee
 
HW
, et al. 
A pilot study of alemtuzumab plus combination chemotherapy for newly diagnosed patients with peripheral T-cell lymphomas [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 4717
76
Intragumtornchai
 
T
Bunworasate
 
U
Nakorn
 
TN
Rojnuckarin
 
P
Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 4740
77
Forero-Torres
 
A
Bernstein
 
SH
Gopal
 
A
, et al. 
SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 2718
78
Ansell
 
SM
Horwitz
 
SM
Engert
 
A
, et al. 
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
J Clin Oncol
2007
, vol. 
25
 
19
(pg. 
2764
-
2769
)
79
Borchmann
 
P
Treml
 
JF
Hansen
 
H
, et al. 
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Blood
2003
, vol. 
102
 
10
(pg. 
3737
-
3742
)
80
Heuck
 
F
Ellermann
 
J
Borchmann
 
P
, et al. 
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.
J Immunother
2004
, vol. 
279
 
5
(pg. 
347
-
353
)
81
Cerveny
 
CG
Law
 
C-L
McCormick
 
RS
, et al. 
The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkins disease growth and sensitizes cells to established chemotherapeutics [abstract].
Blood
2004
, vol. 
104
 
11
 
Abstract 2639
82
Shustov
 
AR
Advani
 
R
, et al. 
Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract].
Blood
2010
, vol. 
116
 
21
 
Abstract 961
83
O'Mahony
 
D
Morris
 
JC
Moses
 
L
, et al. 
Phase I trial of siplizumab in CD2-positive lymphoproliferative disease [abstract].
Blood
2005
, vol. 
106
 
11
 
Abstract 3353
84
Casale
 
DA
Bartlett
 
NL
Hurd
 
DD
, et al. 
A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 2727
85
O'Mahony
 
D
Morris
 
JC
Stetler-Stevenson
 
M
, et al. 
EBV-related lymphoproliferative disease complicating therapy with siplizumab, a novel anti-CD2 mediated T- and NK-cell depleting agent, in patients with T-cell malignancies [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 3565
86
d'Amore
 
F
Radford
 
J
Jerkeman
 
M
, et al. 
Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 3409
87
Bruns
 
I
Fox
 
F
Reinecke
 
P
, et al. 
Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab.
Leukemia
2005
, vol. 
19
 
11
(pg. 
1993
-
1995
)
88
Advani
 
R
Hong
 
F
Ganjoo
 
KN
, et al. 
Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 Trial [abstract].
Blood
2009
, vol. 
114
 
22
 
Abstract 1671
89
Dang
 
NH
Pro
 
B
Hagemeister
 
FB
, et al. 
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Br J Haematol
2007
, vol. 
136
 
3
(pg. 
439
-
447
)
90
Foss
 
F
Sjak-Shie
 
N
Goy
 
A
, et al. 
Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 3449
91
Kreitman
 
RJ
Wilson
 
WH
White
 
JD
, et al. 
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
J Clin Oncol
2000
, vol. 
18
 
8
(pg. 
1622
-
1636
)
92
Olsen
 
EA
Kim
 
YH
Kuzel
 
TM
, et al. 
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
J Clin Oncol
2007
, vol. 
25
 
21
(pg. 
3109
-
3115
)
93
Bates
 
S
Piekarz
 
R
Wright
 
J
, et al. 
Final clinical results of a phase 2 NCI multicenter study of romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included) [abstract].
Blood
2008
, vol. 
112
 
11
 
Abstract 1568
94
Gloucester Pharmaceuticals Inc
Accessed February 8, 2010
Romidepsin: Sponsor's background package for the Oncologic Drugs Advisory Committee Meeting
September 2, 2009
 
95
Piekarz
 
R
Wright
 
J
Frye
 
R
, et al. 
Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) [abstract].
Blood
2009
, vol. 
114
 
22
 
Abstract 1657
96
Pohlman
 
B
Advani
 
R
Duvic
 
M
, et al. 
Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract].
Blood
2009
, vol. 
114
 
22
 
Abstract 920
97
Wang
 
ES
O'Connor
 
O
She
 
Y
, et al. 
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
Leuk Lymphoma
2003
, vol. 
44
 
6
(pg. 
1027
-
1035
)
98
O'Connor
 
OA
Horwitz
 
S
Hamlin
 
P
, et al. 
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
J Clin Oncol
2009
, vol. 
27
 
26
(pg. 
4357
-
4364
)
99
O'Connor
 
OA
Pro
 
B
Pinter-Brown
 
L
, et al. 
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
J Clin Oncol
2011
, vol. 
29
 
9
(pg. 
1182
-
1189
)
100
Crabtree
 
GR
Calcium, calcineurin, and the control of transcription.
J Biol Chem
2001
, vol. 
276
 
4
(pg. 
2313
-
2316
)
101
Advani
 
R
Horwitz
 
S
Zelenetz
 
A
Horning
 
SJ
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.
Leuk Lymphoma
2007
, vol. 
48
 
3
(pg. 
521
-
525
)
102
Joly
 
B
Frenkel
 
V
Gaulard
 
P
, et al. 
Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL): preliminary results in 9 patients treated in a single institution [abstract].
Blood
2005
, vol. 
106
  
Abstract 2686
103
Dueck
 
GS
Chua
 
N
Prasad
 
A
, et al. 
Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases [abstract].
J Clin Oncol
2009
, vol. 
27
 pg. 
439s
 
104
Zinzani
 
PL
Baliva
 
G
Magagnoli
 
M
, et al. 
Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
J Clin Oncol
2000
, vol. 
18
 
13
(pg. 
2603
-
2606
)
105
Marchi
 
E
Alinari
 
L
Tani
 
M
, et al. 
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Cancer
2005
, vol. 
104
 
11
(pg. 
2437
-
2441
)
106
Rupoli
 
S
Goteri
 
G
Picardi
 
P
, et al. 
Alemtuzumab in combination with interferon-α or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results [abstract].
Blood
2008
, vol. 
112
 
11
 
Abstract 5000
107
Evens
 
AM
Gordon
 
LI
Patton
 
D
, et al. 
Phase I results of combination gemcitabine and bortezomib (Velcade) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL) [abstract].
Blood
2008
, vol. 
112
 
11
 
Abstract 2005
108
Dhillon
 
N
Bakkannagari
 
S
Ng
 
C
, et al. 
Cutaneous T cell lymphoma: responses in phase 1 trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 2466
109
Duvic
 
M
Forero-Torres
 
A
Foss
 
F
Olsen
 
EA
Kim
 
Y
Oral forodesine (BCS-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 2467
110
Zinzani
 
PL
Musuraca
 
G
Tani
 
M
, et al. 
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
J Clin Oncol
2007
, vol. 
25
 
27
(pg. 
4293
-
4297
)
111
Delmer
 
A
Fitoussi
 
O
Gaulard
 
P
, et al. 
A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [ASCO abstract 8554].
J Clin Oncol
2009
, vol. 
27
 pg. 
447s
 
112
Marchi
 
E
Paoluzzi
 
L
Venkatraman
 
SE
O'Connor
 
OA
Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid T-cell malignancies [abstract].
Blood
2008
, vol. 
112
 
11
 
Abstract 3619
113
Querfeld
 
C
Rizvi
 
MA
Kuzel
 
TM
, et al. 
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
J Invest Dermatol
2006
, vol. 
126
 
7
(pg. 
1641
-
1647
)
114
Yamaguchi
 
M
Tobinai
 
K
Oguchi
 
M
, et al. 
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
J Clin Oncol
2009
, vol. 
27
 
33
(pg. 
5594
-
5600
)
115
Yong
 
W
Zheng
 
W
Zhang
 
Y
, et al. 
L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.
Int J Hematol
2003
, vol. 
78
 
2
(pg. 
163
-
167
)
116
Yamaguchi
 
M
Kwong
 
Y
Maeda
 
Y
, et al. 
Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK-/T-cell lymphoma, nasal type: NKTSG study [ASCO abstract 8044].
J Clin Oncol
2010
, vol. 
28
 
suppl
pg. 
15
 
117
Tsukasaki
 
K
Utsunomiya
 
A
Fukuda
 
H
, et al. 
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
J Clin Oncol
2007
, vol. 
25
 
34
(pg. 
5458
-
5464
)
118
Gill
 
PS
Harrington
 
W
Kaplan
 
MH
, et al. 
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.
N Engl J Med
1995
, vol. 
332
 
26
(pg. 
1744
-
1748
)
119
Bazarbachi
 
A
Plumelle
 
Y
Carlos
 
RJ
, et al. 
Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
J Clin Oncol
2010
, vol. 
28
 
27
(pg. 
4177
-
4183
)
120
Yamamoto
 
K
Utsunomiya
 
A
Tobinai
 
K
, et al. 
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
J Clin Oncol
2010
, vol. 
28
 
9
(pg. 
1591
-
1598
)
121
Le Gouill
 
S
Milpied
 
N
Buzyn
 
A
, et al. 
Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
J Clin Oncol
2008
, vol. 
26
 
14
(pg. 
2264
-
2271
)
122
d'Amore
 
F
Relander
 
T
Lauritzen
 
G
, et al. 
Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL): a phase II study of the Nordic Lymphoma Group (NLG) [abstract].
Blood
2006
, vol. 
108
 
11
 
Abstract 401
123
Jantunen
 
E
Wiklund
 
T
Juvonen
 
E
, et al. 
Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.
Bone Marrow Transplant
2004
, vol. 
33
 
4
(pg. 
405
-
410
)
124
Smith
 
SD
Bolwell
 
BJ
Rybicki
 
LA
, et al. 
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
Bone Marrow Transplant
2007
, vol. 
40
 
3
(pg. 
239
-
243
)
125
Chen
 
AI
McMillan
 
A
Negrin
 
RS
Horning
 
SJ
Laport
 
GG
Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: the Stanford experience [abstract].
Blood
2007
, vol. 
110
 
11
 
Abstract 1906
126
Reimer
 
P
Rudiger
 
T
Geissinger
 
E
, et al. 
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
J Clin Oncol
2009
, vol. 
27
 
1
(pg. 
106
-
113
)
127
Lansigan
 
F
Seropian
 
S
Cooper
 
D
Foss
 
F
A retrospective comparison of autologous vs. allogeneic transplantation for peripheral T-cell lymphoma: a single institution experience [abstract].
Blood
2008
, vol. 
112
 
11
 
Abstract 4392
128
Sieniawski
 
M
Lennard
 
J
Millar
 
C
, et al. 
Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens [abstract].
Blood
2009
, vol. 
114
 
22
 
Abstract 1660
Sign in via your Institution